GSK1349572 + Efavirenz
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Infections, Human Immunodeficiency Virus and Herpesviridae
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae
Trial Timeline
Mar 16, 2010 → May 26, 2010
NCT ID
NCT01098526About GSK1349572 + Efavirenz
GSK1349572 + Efavirenz is a phase 1 stage product being developed by Shionogi for Infections, Human Immunodeficiency Virus and Herpesviridae. The current trial status is completed. This product is registered under clinical trial identifier NCT01098526. Target conditions include Infections, Human Immunodeficiency Virus and Herpesviridae.
What happened to similar drugs?
20 of 20 similar drugs in Infections, Human Immunodeficiency Virus and Herpesviridae were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01098526 | Phase 1 | Completed |
| NCT00951015 | Phase 2 | Completed |
Competing Products
20 competing products in Infections, Human Immunodeficiency Virus and Herpesviridae